Tubulin beta chain, filamin A alpha isoform 1, and cytochrome b-c1 complex subunit 1 as serological diagnostic biomarkers of esophageal squamous cell carcinoma: A proteomics study

OMICS A Journal of Integrative Biology

Volumn 17, Issue 4, 2013, Pages 215-223

  Fan, Nai Jun ^a   Gao, Chun Fang ^a   Wang, Xiu Li ^a  

^a No 150 Central Hospital of PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; CYTOCHROME B; CYTOCHROME B C1; FILAMIN A; FILAMIN A ALPHA ISOFORM 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PATIENT; CASE CONTROL STUDY; DISEASE MARKER; EARLY DIAGNOSIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PATHOGENESIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SENSITIVITY AND SPECIFICITY;

AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CONTRACTILE PROTEINS; CYTOCHROMES B; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROTEIN ISOFORMS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUBULIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84876112411     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2012.0133     Document Type: Article

References (45)

1. Alper O, Stetler-Stevenson WG, Harris LN, et al. (2009). Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma. Cancer Sci 100, 1748-1756.
2. Arianmanesh M, McIntosh RH, Lea RG, Fowler PA, and Al-Gubory KH. (2011). Ovine corpus luteum proteins, with functions including oxidative stress and lipid metabolism, show complex alterations during implantation. J Endocrinol 210, 47-58.
3. Bedolla RG, Wang Y, Asuncion A, et al. (2009). Nuclear versus cytoplasmic localization of filamin A in prostate cancer: Immunohistochemical correlation with metastases. Clin Cancer Res 15, 788-796.
4. Bouras G, Nakanishi T, Fujita Y, Tsunemi S, Takubo T, and Tanigawa N. (2012). Identification of beta-tubulin as a common immunogen in gastrointestinal malignancy by mass spectrometry of colorectal cancer proteome: Implications for early disease detection. Anal Bioanal Chem 403, 1801-1809.
5. Bryan J, and Wilson L. (1971). Are cytoplasmic microtubules heteropolymers? Proc Natl Acad Sci USA 68, 1762-1766.
6. Daly JM, Fry WA, Little AG, et al. 2000. Esophageal cancer: Results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 190, 562-572; discussion 572-563.
7. Dumontet C, and Jordan MA. (2010). Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat Rev Drug Discov 9, 790-803.
8. Ebert MP, and Rocken C. (2006). Molecular screening of gastric cancer by proteome analysis. Eur J Gastroenterol Hepatol 18, 847-853. (Pubitemid 44034797)
9. Edge SB, and Compton CC. (2010). TheAmerican Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17, 1471-1474.
10. Fan NJ, Gao CF, Wang CS, et al. (2012a). Discovery and verification of gelsolin as a potential biomarker of colorectal adenocarcinoma in the Chinese population: Examining differential protein expression using an iTRAQ labelling-based proteomics approach. Can J Gastroenterol 26, 41-47.
11. Fan NJ, Gao CF, and Wang XL. (2011). Identification of regional lymph node involvement of colorectal cancer by serum SELDI proteomic patterns. Gastroenterol Res Pract 2011, 784967.
12. Fan NJ, Gao CF, Zhao G, Wang XL, and Liu QY. (2012b). Serum peptidome patterns of breast cancer based on magnetic bead separation and mass spectrometry analysis. Diagn Pathol 7, 45.
13. Fan NJ, Gao CF, Zhao G, Wang XL, and Qiao L. (2012c). Serum peptidome patterns for early screening of esophageal squamous cell carcinoma. Biotechnol Appl Biochem 59, 276-282.
14. Fan NJ, Gao CF, Wang CS, et al. (2012). Identification of the upregulation of TP-alpha, collagen alpha-1(VI) chain, and S100A9 in esophageal squamous cell carcinoma by a proteomic method. J Proteom 75, 3977-3986.
15. Gabellini N. (1988). Organization and structure of the genes for the cytochrome b/c1 complex in purple photosynthetic bacteria. A phylogenetic study describing the homology of the b/c1 subunits between prokaryotes, mitochondria, and chloroplasts. J Bioenerg Biomembr 20, 59-83. (Pubitemid 18039574)
16. Hartwig JH, and Stossel TP. (1975). Isolation and properties of actin, myosin, and a new actin binding protein in rabbit alveolar macrophages. J Biol Chem 250, 5696-5705.
17. Holmes RS, and Vaughan TL. (2007). Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 17, 2-9. (Pubitemid 44918357)
18. Hudler P, Gorsic M, and Komel R. (2010). Proteomic strategies and challenges in tumor metastasis research. Clin Exp Metastasis 27, 441-451.
19. Iizuka T, Isono K, Kakegawa T, and Watanabe H. (1989). Parameters linked to ten-year survival in Japan of resected esophageal carcinoma. Japanese Committee for Registration of Esophageal Carcinoma Cases. Chest 96, 1005-1011. (Pubitemid 19266548)
20. Issaq HJ, Xiao Z, and Veenstra TD. (2007). Serum and plasma proteomics. Chem Rev 107, 3601-3620. (Pubitemid 47333550)
21. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D. (2011). Global cancer statistics. CA Cancer J Clin 61, 69-90.
22. Kashyap MK, Harsha HC, Renuse S, et al. (2010). SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome. Cancer Biol Ther 10, 796-810.
23. Kavallaris M. (2010). Microtubules and resistance to tubulinbinding agents. Nat Rev Cancer 10, 194-204.
24. Kelly P, Appleyard V, Murray K, et al. (2010). Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy. Br J Cancer 103, 232-238.
25. Keshamouni VG, Michailidis G, Grasso CS, et al. (2006). Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res 5, 1143-1154. (Pubitemid 43727792)
26. Ketterlinus R, Hsieh SY, Teng SH, Lee H, and Pusch W, (2005). Fishing for biomarkers: Analyzing mass spectrometry data with the new ClinProTools software. Biotechniques Suppl, 37-40.
27. Kilpatrick LA, Labus JS, Coveleskie K, et al. (2011). The HTR3A polymorphism c.-42C T is associated with amygdala responsiveness in patients with irritable bowel syndrome. Gastroenterology 140, 1943-1951.
28. Li C, Xin W, and Sy MS. 2010. Binding of pro-prion to filamin A: By design or an unfortunate blunder. Oncogene 29, 5329-5345.
29. Lin HB, Cadete VJ, Sawicka J, Wozniak M, and Sawicki G. (2012). Effect of the myosin light chain kinase inhibitor ML-7 on the proteome of hearts subjected to ischemia-reperfusion injury. J Proteom 75, 5386-5395.
30. Liu LH, Shan BE, and Tian ZQ, et al. (2010). Potential biomarkers for esophageal carcinoma detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem Lab Med 48, 855-861.
31. Nakamura F, Stossel TP, and Hartwig JH. (2011). The filamins: Organizers of cell structure and function. Cell Adh Migr 5, 160-169.
32. Pan C, He N, Zhao M, et al. 2011. Subdividing the M1 stage of liver metastasis for nasopharyngeal carcinoma to better predict metastatic survival. Med Oncol 28, 1349-1355.
33. Pawar H, Kashyap MK, Sahasrabuddhe NA, et al. (2011). Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery. Cancer Biol Ther 12, 510-522.
34. Perez EA. (2009). Microtubule inhibitors: Differentiating tubulininhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 8, 2086-2095.
35. Qasim M, Rahman H, Oellerich M, and Asif AR. (2011). Differential proteome analysis of human embryonic kidney cell line (HEK-293) following mycophenolic acid treatment. Proteome Sci 9, 57.
36. Singh PK, Brand RE, and Mehla K. (2012). MicroRNAs in pancreatic cancer metabolism. Nat Rev Gastroenterol Hepatol 9, 334-344.
37. Swets JA. (1988). Measuring the accuracy of diagnostic systems. Science 240, 1285-1293.
38. Tang W, Shi YQ, Zou JJ, et al. (2011). Serum biomarker of diabetic peripheral neuropathy indentified by differential proteomics. Front Biosci 16, 2671-2681.
39. Triboulet JP, Mariette C, Chevalier D, and Amrouni H. (2001). Surgical management of carcinoma of the hypopharynx and cervical esophagus: Analysis of 209 cases. Arch Surg 136, 1164-1170. (Pubitemid 32929345)
40. Uhlen M, Bjorling E, Agaton C, et al. (2005). A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteom 4, 1920-1932. (Pubitemid 41830186)
41. Wulfkuhle JD, Liotta LA, and Petricoin EF. (2003). Proteomic applications for the early detection of cancer. Nat Rev Cancer 3, 267-275. (Pubitemid 37328862)
42. Yeh IT, and Luduena RF. (2004). The betaII isotype of tubulin is present in the cell nuclei of a variety of cancers. Cell Motil Cytoskeleton 57, 96-106. (Pubitemid 38134050)
43. Yue J, Wang Q, Lu H, Brenneman M, Fan F, and Shen Z. (2009). The cytoskeleton protein filamin-A is required for an efficient recombinational DNA double strand break repair. Cancer Res 69, 7978-7985.
44. Zethelius B, Berglund L, Sundstrom J, et al. (2008). Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358, 2107-2116. (Pubitemid 351679597)
45. Zhang J, Wang K, Liu SS, Dai L, and Zhang JY. (2011). Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. J Proteome Res 10, 2863-2872.